Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Reliq Health Technologies Inc V.RHT

Alternate Symbol(s):  RQHTF

Reliq Health Technologies Inc. is a Canada-based global healthcare technology company that specializes in developing virtual care solutions. The Company's target markets include virtual care, long-term care and big data. iUGO Care, the Company's platform, is a software as a service solution that supports care coordination and community-based healthcare. The iUGO Care platform integrates wearables, sensors, voice technology and mobile apps and desktop user interfaces for patients, clinicians and healthcare administrators. The iUGO Care platform provides services, such as remote patient monitoring, chronic care management, principal care management, behavioral health integration, telemedicine, transitional care management, remote therapeutic monitoring and wound care. Its behavioral health integration service supports patients with any mental, behavioral, or psychiatric health diagnoses by integrating mental health, psychiatric care, counseling, and addiction services with primary care.


TSXV:RHT - Post by User

Post by theinvestor22on Mar 09, 2023 10:43am
609 Views
Post# 35328066

Fair Value of SNFs to Reliq

Fair Value of SNFs to Reliq
Let's look at the potential value add for SNFs alone.  According to data unearthed by mingzhu, there are 15,183 SNFs in the US.  Reliq signed contracts since October covering about 214 of them, for about a 1.41% market share in just around 5 months.  Assuming they get only 10% of this market (which to me seems very low), assuming they get 70% adherence (because patients get trained before they leave the facilities), assuming 30% of those patients are converted to long term monitoring contracts (the company says it's way higher than that - 80% - so far) and assuming no collections problems (because SNF are more professional organizations), here's what I get.
 
Yearly Transitional Revenue: (10% of 15,183 SNFs) x (70% adherence for 100 patients per SNF added each month) x US$65 x 1.35 forex x 12 months = CAD$112M
 
Yearly Monitoring ARR:  106,281 new adherent patients each month x 30% conversion rate x say US$60/mth x 1.35 forex x 12 months = CAD$31M for each new month's worth of patient discharges.  Multiply that by 12  (because there are 12 month's worth of discharges each year) to get the full annualized amount, so CAD$31M x 12 = $CAD372M.
 
Based on company provided info, net (i.e., profit)  margin should be about 45% EBITDA margin (less a smidge for depreciation/amortization) x 73.5% tax rate, or about 33%.  Let's be conservative and use 25%, which yields a net margin of (CAD$112M + CAD$372M) x 25% = CAD$121M
 
Earnings per share (EPS) would therefore be about CAD$121M / say 225M shares (assuming more options and little buy-back) = $0.54.
 
So, for a 10% market share, the company's fair value might increase by say $0.54 x a 20-30x price/earnings multiple = CAD$10.80 to CAD$16.20.
 
If you don't like reasonable projections and want to stick just with announced contracts, the value add so far would be 1.41%/10% x the values in the preceding paragraph = CAD$1.52 to CAD$2.28.
 
So, even if the company lags in the development of its non-SNF business, enters no new niches and gets nothing from its Cognizant partnership, it's still cheap based only upon the SNF niche.
 
[All done without the use of revenue multiples.]
 
That's why I'm so pleased to see progress in the SNF space.
<< Previous
Bullboard Posts
Next >>